Hello Sir,
Hope you are doing well.
Everyone is looking for good investment opportunities that can turn out to be multibaggers.
I was recently looking at Sigachi Industries. It makes excipients and supplies to pharma, food and cosmetics companies. Excipient is basically a constituent of medicine other than active substance, i.e., other than say API. It generally aids in lubricity, flowability, disintegration, taste, etc.
Before that: As on 7th Nov’24, 23 medium/long term stock recommendations are under coverage. Out of the same, 7 are both Positive rated and in the buy zone.
Recently, we also released a new report on Strong growth Chemical Stock available at < 1 time book value. You can get these 23 recommendations including the new one by signing up HERE
Coming back to Sigachi, the company has recently expanded capacity for MCC (excipient), acquired an API unit and setting up CCS facility. Management is also looking to reduce debt.
Below, we have shared our notes from the Q1 FY 25 con-call of the company to understand the outlook for the business.
Sigachi Industries – Notes from Q2 FY 25 concall
– Overview:
- Sigachi Industries, a leading manufacturer of excipients, operates across three main segments: excipients (primarily microcrystalline cellulose or MCC), operations and management (O&M), and active pharmaceutical ingredients (API)
- Core MCC segment is known for its unique binding properties, making it a preferred choice for directly compressible binders and offering broad compatibility with APIs
- Manufacturing facilities for MCC are located in Dahej, Jhagadia, and Hyderabad, with a combined capacity of 21,000 metric tonnes per annum
- In the O&M segment, Sigachi has partnerships with notable companies like Gujarat Alkalis, Aditya Birla Group, ONGC, and Lord’s Chloro
- In the API segment, last year it acquired Trimax Bio Sciences with a production capacity of 100 KL, with plans to expand to 250 KL at an estimated CAPEX of Rs 60 crores
- Sigachi is setting up CCS (Cross Carmellose Sodium) facility at Dahej with an initial production capacity of 1,800 metric tonnes per annum, scalable up to 3,600 MTPA, at an estimated CAPEX of Rs 90 crores
- The MCC and CCS customer bases complement each other, with potential overlaps for API customers.
– Performance:
- MCC revenue grew by 2.79% YoY, from Rs. 69.88 crores to Rs. 71.83 crores
- O&M revenue increased by 18.54% in Q1 FY 2025, from Rs. 8.52 crores to Rs. 10.10 crores
- API segment revenue for Q1 FY 2025 stood at Rs. 8.99 crores
– MCC Segment:
- Two-thirds of MCC revenue is from exports, with regulated markets like the US, Europe, Australia, and the UK accounting for nearly 50% of sales
- Capacity utilization as of March 31, 2024, was around 94%
- Q1 FY 2025 capacity utilization: Dahej at 56%, Jhagadia at 53%, and Hyderabad at 86% (overall 66%)
- Capacity increased by 7,000 metric tonnes across Jhagadia and Dahej
– O&M Segment:
- Sigachi operates and manages plants on behalf of large chemical companies, offering cost savings, yield improvements, and higher earnings for clients
- Solar power is a recent addition, with competencies built over the past 15 months
- Desalination is an emerging area of focus in the Middle East subsidiary, with national-level contracts
- EBITDA margin typically ranges between 21% and 23%
– API Segment:
- Currently focused on the domestic market but aims to expand into regulated markets, expecting regulatory approvals in 9-12 months
- Filed three CEP (Certificate of Suitability of Monographs) filings in the European Union
- Targeting nine CEP filings for the current financial year
- Capacity utilization is around 70%
– Balance Sheet:
- Aiming for near-zero debt by the end of FY 2025
- Working to reduce collection and debtor periods
- The amount from preferential share warrants will be used to repay debt, ensuring no long-term debt for FY 2025
– Guidance:
- Historically maintained a 25% CAGR and is focused on sustaining or improving this growth rate in the future
(End)
Disclaimer: This is not a recommendation to buy/sell any of the stocks mentioned above. The securities quoted are for illustration only and are not recommendatory.
Best Regards,
Ekansh Mittal
Research Analyst
Web: https://www.katalystwealth.
SEBI Research Analyst Registration No. INH100001690
Research Analyst Details
Name: Ekansh Mittal Email Id: [email protected] Ph: +91 727 5050062
Details of Associate: Not Applicable
Analyst Certification: The Analyst certify (ies) that the views expressed herein accurately reflect his (their) personal view(s) about the subject security (ies) and issuer(s) and that no part of his (their) compensation was, is or will be directly or indirectly related to the specific recommendation(s) or views contained in this research report.
Disclaimer: http://www.
Address – 7, Panch Ratan, 7/128, Swaroop Nagar, Kanpur – 208002, Contact No. – +91-7275050062
Compliance Officer – Mr. Ekansh Mittal, +91-9818866676, ekansh@
Grievance Redressal – Mittal Consulting, grievances@
“Registration granted by SEBI and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors”.
“Investment in securities market are subject to market risks. Read all the related documents carefully before investing.”
The views expressed are based solely on information available publicly and believed to be true. Investors are advised to independently evaluate the market conditions/risks involved before making any investment decision
This report is for the personal information of the authorized recipient and does not construe to be any investment, legal or taxation advice to you. Ekansh Mittal/Mittal Consulting/Katalyst Wealth is not soliciting any action based upon it. This report is not for public distribution and has been furnished to you solely for your information and should not be reproduced or redistributed to any other person in any form. This document is provided for assistance only and is not intended to be and must not alone be taken as the basis for an investment decision. Ekansh Mittal or any of its affiliates or employees shall not be in any way responsible for any loss or damage that may arise to any person from any inadvertent error in the information contained in this report. Neither Ekansh Mittal, nor its employees, agents nor representatives shall be liable for any damages whether direct or indirect, incidental, special or consequential including lost revenue or lost profits that may arise from or in connection with the use of the information. Ekansh Mittal/Mittal Consulting or any of its affiliates or employees do not provide, at any time, any express or implied warranty of any kind, regarding any matter pertaining to this report, including without limitation the implied warranties of merchantability, fitness for a particular purpose, and non-infringement.
The recipients of this report should rely on their own investigations. Ekansh Mittal/Mittal Consulting and/or its affiliates and/or employees may have interests/ positions, financial or otherwise in the securities mentioned in this report. Mittal Consulting has incorporated adequate disclosures in this document. This should, however, not be treated as endorsement of the views expressed in the report.
We submit that no material disciplinary action has been taken on Ekansh Mittal by any regulatory authority impacting Equity Research Analysis.
Disclaimer: You can access it here – LINK
Whether the research analyst or research entity or his associate or his relative has any financial interest in the subject company/companies and the nature of such financial interest – No
Whether the research analyst or research entity or his associates or his relatives have actual/beneficial ownership of 1% or more securities of the subject company (at the end of the month immediately preceding the date of publication of the research report or date of the public appearance) – No
Whether the research analyst or research entity or his associate or his relative has any other material conflict of interest at the time of publication of the research report or at the time of public appearance – No
Whether it or its associates have received any compensation from the subject company in the past twelve months – No
Whether it or its associates have managed or co-managed public offering of securities for the subject company in the past 12 months – No
Whether it or its associates have received any compensation for investment banking or merchant banking or brokerage services from the subject company in the past 12 months – No
Whether it or its associates have received any compensation for products or services other than investment banking or merchant banking or brokerage services from the subject company in the past 12 months – No
Whether the subject company is or was a client during twelve months preceding the date of distribution of the research report and the types of services provided – No
Whether the research analyst has served as an officer, director or employee of the subject company – No
Whether the research analyst or research entity has been engaged in market making activity for the subject company – No